Prestige Consumer Healthcare (PBH) Non-Current Assets (2011 - 2026)
Prestige Consumer Healthcare (PBH) posted quarterly Non-Current Assets of $3.1 billion for Q4 2025, up 3.69% year-over-year from $3.0 billion in Q4 2024, and up 3.95% quarter-over-quarter from $2.9 billion in Q3 2025.
Prestige Consumer Healthcare (PBH) Non-Current Assets (2011 - 2026) Analysis & Trends
Prestige Consumer Healthcare's Non-Current Assets history runs 15 years deep, the most recent figure standing at $3.1 billion for Q4 2025.
- In Q4 2025, Non-Current Assets rose 3.69% year-over-year to $3.1 billion; the TTM figure through Dec 2025 stood at $11.9 billion (up 1.19% YoY), while the FY2025 annual figure was $3.0 billion, changed 0.36% from the prior year.
- Non-Current Assets for Q4 2025 stood at $3.1 billion, up from $2.9 billion in the prior quarter.
- The five-year high for Non-Current Assets was $3.4 billion in Q4 2021, with the low at $2.9 billion in Q3 2024.
- The 5-year median for Non-Current Assets is $3.0 billion (2023), against an average of $3.1 billion.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets rose 6.9% in 2022, then decreased 12.3% in 2023.
- Prestige Consumer Healthcare's Non-Current Assets stood at $3.4 billion in 2021, then slipped by 1.28% to $3.3 billion in 2022, then slipped by 11.82% to $2.9 billion in 2023, then gained by 0.22% to $3.0 billion in 2024, then grew by 3.69% to $3.1 billion in 2025.
- Business Quant data shows PBH's Non-Current Assets at $3.1 billion in Q4 2025, $2.9 billion in Q3 2025, and $3.0 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Prestige Consumer Healthcare | 2.44 Bn | 2.38 Bn | - | 3.06 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.06 Bn |
| Dec 31, 2025 | 3.06 Bn |
| Sep 30, 2025 | 2.94 Bn |
| Jun 30, 2025 | 2.95 Bn |
| Mar 31, 2025 | 2.95 Bn |
| Dec 31, 2024 | 2.95 Bn |
| Sep 30, 2024 | 2.94 Bn |
| Jun 30, 2024 | 2.94 Bn |
| Mar 31, 2024 | 2.94 Bn |
| Dec 31, 2023 | 2.95 Bn |
| Sep 30, 2023 | 2.94 Bn |
| Jun 30, 2023 | 2.95 Bn |
| Mar 31, 2023 | 2.96 Bn |
| Dec 31, 2022 | 3.34 Bn |
| Sep 30, 2022 | 3.34 Bn |
| Jun 30, 2022 | 3.36 Bn |
| Mar 31, 2022 | 3.38 Bn |
| Dec 31, 2021 | 3.38 Bn |
| Sep 30, 2021 | 3.37 Bn |
| Jun 30, 2021 | 3.15 Bn |